Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Spyre Therapeutics has announced a proposed underwritten public offering of common stock to secure funding for its ongoing development programs. The proceeds will primarily support advancing its Gastroenterology, Rheumatology, and Dermatology programs through clinical stages, including Phase 3 readiness, and initiating late-stage development for SPY072 in hidradenitis suppurativa. The offering's completion is contingent on market and other conditions.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.